|
BIOLASE, INC.
Schedule II — Consolidated Valuation and Qualifying Accounts and Reserves
For the Years Ended December 31, 2023, 2022, and 2021
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
Charges |
|
|
|
|
|
|
|
|
|
Beginning |
|
|
(Reversals) to Cost |
|
|
|
|
|
Balance at |
|
|
|
of Year |
|
|
or Expenses |
|
|
Deductions |
|
|
End of Year |
|
Year Ended December 31, 2021: |
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts |
|
$ |
4,017 |
|
|
$ |
(202 |
) |
|
$ |
(1,661 |
) |
|
$ |
2,154 |
|
Allowance for sales returns |
|
|
262 |
|
|
|
— |
|
|
|
— |
|
|
|
262 |
|
Allowance for tax valuation |
|
|
21,743 |
|
|
|
5,518 |
|
|
|
— |
|
|
|
27,261 |
|
Year Ended December 31, 2022: |
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts |
|
$ |
2,154 |
|
|
$ |
(12 |
) |
|
$ |
22 |
|
|
$ |
2,164 |
|
Allowance for sales returns |
|
|
262 |
|
|
|
— |
|
|
|
— |
|
|
|
262 |
|
Allowance for tax valuation |
|
|
27,261 |
|
|
|
(4 |
) |
|
|
3,978 |
|
|
|
31,235 |
|
Year Ended December 31, 2023: |
|
|
|
|
|
|
|
|
|
|
|
|
Allowance for doubtful accounts |
|
$ |
2,164 |
|
|
$ |
(2,034 |
) |
|
$ |
114 |
|
|
$ |
244 |
|
Allowance for sales returns |
|
|
262 |
|
|
|
— |
|
|
|
— |
|
|
|
262 |
|
Allowance for tax valuation |
|
|
31,235 |
|
|
|
(24 |
) |
|
|
4,595 |
|
|
|
35,806 |
|
|